Submitted:
11 June 2024
Posted:
12 June 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. HD Pathophysiology
3. Current and Prospective Treatments
4. Glial Cells – HD
4.1. Microglia - HD
4.2. Astroglia (Astrocytes) - HD
4.3. Oligodendrocytes - HD
4.4. Synantocytes (NG2 cells) - HD
5. Gut Microbiota
6. Gut-Brain Axis
7. Heavy Metals
7.1. Iron (Fe) - HD
7.2. Manganese (Mn) – HD
7.3. Copper (Cu) - HD
8. Heavy metals - GM - HD
9. Conclusion
Author Contributions
Funding
Conflicts of Interest
References
- Ajitkumar: A.; De Jesus, O. Huntington Disease. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2024.
- D’Egidio, F.; Castelli, V.; Lombardozzi, G.; Ammannito, F.; Cimini, A.; d’Angelo, M. Therapeutic Advances in Neural Regeneration for Huntington’s Disease. Neural Regen. Res. 2024, 19, 1991–1997, . [CrossRef]
- Finkbeiner, S. Huntington’s Disease. Cold Spring Harb. Perspect. Biol. 2011, 3, a007476, . [CrossRef]
- Barron, J.C.; Hurley, E.P.; Parsons, M.P. Huntingtin and the Synapse. Front. Cell. Neurosci. 2021, 15, 689332, . [CrossRef]
- Rawlins, M.D.; Wexler, N.S.; Wexler, A.R.; Tabrizi, S.J.; Douglas, I.; Evans, S.J.W.; Smeeth, L. The Prevalence of Huntington’s Disease. Neuroepidemiology 2016, 46, 144–153, . [CrossRef]
- Pringsheim, T.; Wiltshire, K.; Day, L.; Dykeman, J.; Steeves, T.; Jette, N. The Incidence and Prevalence of Huntington’s Disease: A Systematic Review and Meta-analysis. Mov. Disord. 2012, 27, 1083–1091, . [CrossRef]
- Kim, A.; Lalonde, K.; Truesdell, A.; Gomes Welter, P.; Brocardo, P.S.; Rosenstock, T.R.; Gil-Mohapel, J. New Avenues for the Treatment of Huntington’s Disease. Int. J. Mol. Sci. 2021, 22, 8363, . [CrossRef]
- Khoshnan, A. Gut Microbiota as a Modifier of Huntington’s Disease Pathogenesis. J. Huntingt. Dis. 2024, 1–15, . [CrossRef]
- Estevam, B.; Matos, C.A.; Nóbrega, C. PolyQ Database—an Integrated Database on Polyglutamine Diseases. Database 2023, 2023, baad060, . [CrossRef]
- Caron, N.S.; Wright, G.E.; Hayden, M.R. Huntington Disease. In GeneReviews®; Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., Amemiya, A., Eds.; University of Washington, Seattle: Seattle (WA), 1993.
- Crotti, A.; Glass, C.K. The Choreography of Neuroinflammation in Huntington’s Disease. Trends Immunol. 2015, 36, 364–373, . [CrossRef]
- Palpagama, T.H.; Waldvogel, H.J.; Faull, R.L.M.; Kwakowsky, A. The Role of Microglia and Astrocytes in Huntington’s Disease. Front. Mol. Neurosci. 2019, 12, 258, . [CrossRef]
- Donley, D.W.; Realing, M.; Gigley, J.P.; Fox, J.H. Iron Activates Microglia and Directly Stimulates Indoleamine-2,3-Dioxygenase Activity in the N171-82Q Mouse Model of Huntington’s Disease. PLOS ONE 2021, 16, e0250606, . [CrossRef]
- Lobato, A.G.; Ortiz-Vega, N.; Zhu, Y.; Neupane, D.; Meier, K.K.; Zhai, R.G. Copper Enhances Aggregational Toxicity of Mutant Huntingtin in a Drosophila Model of Huntington’s Disease. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 2024, 1870, 166928, . [CrossRef]
- Paleacu, D. Tetrabenazine in the Treatment of Huntington’s Disease. Neuropsychiatr. Dis. Treat. 2007, 3, 545–551.
- Ferguson, M.W.; Kennedy, C.J.; Palpagama, T.H.; Waldvogel, H.J.; Faull, R.L.M.; Kwakowsky, A. Current and Possible Future Therapeutic Options for Huntington’s Disease. J. Cent. Nerv. Syst. Dis. 2022, 14, 11795735221092517, . [CrossRef]
- Sheridan, C. Questions Swirl around Failures of Disease-Modifying Huntington’s Drugs. Nat. Biotechnol. 2021, 39, 650–652, . [CrossRef]
- Dash, D.; Mestre, T.A. Therapeutic Update on Huntington’s Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. Neurotherapeutics 2020, 17, 1645–1659, . [CrossRef]
- Alkanli, S.S.; Alkanli, N.; Ay, A.; Albeniz, I. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease. Mol. Neurobiol. 2023, 60, 1486–1498, . [CrossRef]
- Tabrizi, S.J.; Estevez-Fraga, C.; van Roon-Mom, W.M.C.; Flower, M.D.; Scahill, R.I.; Wild, E.J.; Muñoz-Sanjuan, I.; Sampaio, C.; Rosser, A.E.; Leavitt, B.R. Potential Disease-Modifying Therapies for Huntington’s Disease: Lessons Learned and Future Opportunities. Lancet Neurol. 2022, 21, 645–658, . [CrossRef]
- Raymond, L.A. Excitotoxicity in Huntington Disease. Clin. Neurosci. Res. 2003, 3, 121–128, . [CrossRef]
- Kang, R.; Wang, L.; Sanders, S.S.; Zuo, K.; Hayden, M.R.; Raymond, L.A. Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Front. Synaptic Neurosci. 2019, 11, 3, . [CrossRef]
- Gao, J.; Wang, H.; Liu, Y.; Li, Y.-Y.; Chen, C.; Liu, L.-M.; Wu, Y.-M.; Li, S.; Yang, C. Glutamate and GABA Imbalance Promotes Neuronal Apoptosis in Hippocampus after Stress. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2014, 20, 499–512, . [CrossRef]
- Saigoh, K.; Hirano, M.; Mitsui, Y.; Oda, I.; Ikegawa, A.; Samukawa, M.; Yoshikawa, K.; Yamagishi, Y.; Kusunoki, S.; Nagai, Y. Memantine Administration Prevented Chorea Movement in Huntington’s Disease: A Case Report. J. Med. Case Reports 2023, 17, 431, . [CrossRef]
- Verhagen Metman, L.; Morris, M.J.; Farmer, C.; Gillespie, M.; Mosby, K.; Wuu, J.; Chase, T.N. Huntington’s Disease: A Randomized, Controlled Trial Using the NMDA-Antagonist Amantadine. Neurology 2002, 59, 694–699, . [CrossRef]
- Vonsattel, J.P.G.; Keller, C.; Pilar Amaya, M.D. Neuropathology of Huntington’s Disease. In Handbook of Clinical Neurology; Elsevier, 2008; Vol. 89, pp. 599–618 ISBN 978-0-444-51898-9.
- Sapp, E.; Kegel, K.B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; Difiglia, M. Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain. J. Neuropathol. Exp. Neurol. 2001, 60, 161–172, . [CrossRef]
- Tizabi, Y.; Getachew, B.; Hauser, S.R.; Tsytsarev, V.; Manhães, A.C.; Da Silva, V.D.A. Role of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction. Brain Sci. 2024, 14, 558, . [CrossRef]
- Saba, J.; Couselo, F.L.; Bruno, J.; Carniglia, L.; Durand, D.; Lasaga, M.; Caruso, C. Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyteand Microglia. Curr. Neuropharmacol. 2022, 20, 1116–1143, . [CrossRef]
- Sanadgol, N. Editorial: Glial Cells as an Emerging Therapeutic Target in the Pathobiology of Central Nervous System Disorders: Friend or Foe? Front. Cell. Neurosci. 2023, 17, 1191743, . [CrossRef]
- Carvalho, F.V.; Landis, H.E.; Getachew, B.; Diogenes Amaral Silva, V.; Ribeiro, P.R.; Aschner, M.; Tizabi, Y. Iron Toxicity, Ferroptosis and Microbiota in Parkinson’s Disease: Implications for Novel Targets. In Advances in Neurotoxicology; Elsevier, 2024; Vol. 11, pp. 105–132 ISBN 978-0-443-21560-5.
- Pathak, D.; Sriram, K. Neuron-Astrocyte Omnidirectional Signaling in Neurological Health and Disease. Front. Mol. Neurosci. 2023, 16, 1169320, . [CrossRef]
- Soares, É.N.; Costa, A.C.D.S.; Ferrolho, G.D.J.; Ureshino, R.P.; Getachew, B.; Costa, S.L.; Da Silva, V.D.A.; Tizabi, Y. Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease. Cells 2024, 13, 474, . [CrossRef]
- Saitgareeva, A.R.; Bulygin, K.V.; Gareev, I.F.; Beylerli, O.A.; Akhmadeeva, L.R. The Role of Microglia in the Development of Neurodegeneration. Neurol. Sci. 2020, 41, 3609–3615, . [CrossRef]
- Gao, C.; Jiang, J.; Tan, Y.; Chen, S. Microglia in Neurodegenerative Diseases: Mechanism and Potential Therapeutic Targets. Signal Transduct. Target. Ther. 2023, 8, 359, . [CrossRef]
- De Marchi, F.; Munitic, I.; Vidatic, L.; Papić, E.; Rački, V.; Nimac, J.; Jurak, I.; Novotni, G.; Rogelj, B.; Vuletic, V.; et al. Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders. Biomedicines 2023, 11, 2793, . [CrossRef]
- Fatoba, O.; Itokazu, T.; Yamashita, T. Microglia as Therapeutic Target in Central Nervous System Disorders. J. Pharmacol. Sci. 2020, 144, 102–118, . [CrossRef]
- Heidari, A.; Yazdanpanah, N.; Rezaei, N. The Role of Toll-like Receptors and Neuroinflammation in Parkinson’s Disease. J. Neuroinflammation 2022, 19, 135, . [CrossRef]
- Liao, X.; Zhu, W.; Liao, X.; Liu, W.; Hou, Y.; Wan, J. Expression of Toll-like Receptors in the Cerebellum during Pathogenesis of Prion Disease. Front. Behav. Neurosci. 2024, 18, 1341901, . [CrossRef]
- Martínez-Hernández, M.I.; Acosta-Saavedra, L.C.; Hernández-Kelly, L.C.; Loaeza-Loaeza, J.; Ortega, A. Microglial Activation in Metal Neurotoxicity: Impact in Neurodegenerative Diseases. BioMed Res. Int. 2023, 2023, 1–27, . [CrossRef]
- Vainchtein, I.D.; Molofsky, A.V. Astrocytes and Microglia: In Sickness and in Health. Trends Neurosci. 2020, 43, 144–154, . [CrossRef]
- Kotliarova, A.; Sidorova, Y.A. Glial Cell Line-Derived Neurotrophic Factor Family Ligands, Players at the Interface of Neuroinflammation and Neuroprotection: Focus Onto the Glia. Front. Cell. Neurosci. 2021, 15, 679034, . [CrossRef]
- Garland, E.F.; Hartnell, I.J.; Boche, D. Microglia and Astrocyte Function and Communication: What Do We Know in Humans? Front. Neurosci. 2022, 16, 824888, . [CrossRef]
- Verkhratsky, A.; Nedergaard, M. Physiology of Astroglia. Physiol. Rev. 2018, 98, 239–389, . [CrossRef]
- Stoklund Dittlau, K.; Freude, K. Astrocytes: The Stars in Neurodegeneration? Biomolecules 2024, 14, 289, . [CrossRef]
- Heir, R.; Abbasi, Z.; Komal, P.; Altimimi, H.F.; Franquin, M.; Moschou, D.; Chambon, J.; Stellwagen, D. Astrocytes Are the Source of TNF Mediating Homeostatic Synaptic Plasticity. J. Neurosci. 2024, 44, e2278222024, . [CrossRef]
- Rajkowska, G.; Stockmeier, C. Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue. Curr. Drug Targets 2013, 14, 1225–1236, . [CrossRef]
- Patani, R.; Hardingham, G.E.; Liddelow, S.A. Functional Roles of Reactive Astrocytes in Neuroinflammation and Neurodegeneration. Nat. Rev. Neurol. 2023, 19, 395–409, . [CrossRef]
- Giovannoni, F.; Quintana, F.J. The Role of Astrocytes in CNS Inflammation. Trends Immunol. 2020, 41, 805–819, . [CrossRef]
- Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms Underlying Inflammation in Neurodegeneration. Cell 2010, 140, 918–934, . [CrossRef]
- Pamphlett, R.; Bishop, D.P. The Toxic Metal Hypothesis for Neurological Disorders. Front. Neurol. 2023, 14, 1173779, . [CrossRef]
- Cheli, V.T.; Correale, J.; Paez, P.M.; Pasquini, J.M. Iron Metabolism in Oligodendrocytes and Astrocytes, Implications for Myelination and Remyelination. ASN Neuro 2020, 12, 175909142096268, . [CrossRef]
- Li, B.; Xia, M.; Zorec, R.; Parpura, V.; Verkhratsky, A. Astrocytes in Heavy Metal Neurotoxicity and Neurodegeneration. Brain Res. 2021, 1752, 147234, . [CrossRef]
- Joshi, P.; Bodnya, C.; Ilieva, I.; Neely, M.D.; Aschner, M.; Bowman, A.B. Huntington’s Disease Associated Resistance to Mn Neurotoxicity Is Neurodevelopmental Stage and Neuronal Lineage Dependent. NeuroToxicology 2019, 75, 148–157, . [CrossRef]
- Tizabi, Y.; Bennani, S.; El Kouhen, N.; Getachew, B.; Aschner, M. Interaction of Heavy Metal Lead with Gut Microbiota: Implications for Autism Spectrum Disorder. Biomolecules 2023, 13, 1549, . [CrossRef]
- Michalski, J.-P.; Kothary, R. Oligodendrocytes in a Nutshell. Front. Cell. Neurosci. 2015, 9, . [CrossRef]
- Bsibsi, M.; Nomden, A.; Van Noort, J.M.; Baron, W. Toll-like Receptors 2 and 3 Agonists Differentially Affect Oligodendrocyte Survival, Differentiation, and Myelin Membrane Formation. J. Neurosci. Res. 2012, 90, 388–398, . [CrossRef]
- Kumar, V. Toll-Like Receptors in Adaptive Immunity. In Toll-like Receptors in Health and Disease; Kumar, V., Ed.; Handbook of Experimental Pharmacology; Springer International Publishing: Cham, 2021; Vol. 276, pp. 95–131 ISBN 978-3-031-06511-8.
- Sanchez-Petidier, M.; Guerri, C.; Moreno-Manzano, V. Toll-like Receptors 2 and 4 Differentially Regulate the Self-Renewal and Differentiation of Spinal Cord Neural Precursor Cells. Stem Cell Res. Ther. 2022, 13, 117, . [CrossRef]
- Sun, Y.; Tong, H.; Yang, T.; Liu, L.; Li, X.-J.; Li, S. Insights into White Matter Defect in Huntington’s Disease. Cells 2022, 11, 3381, . [CrossRef]
- Maiuolo, J.; Macrì, R.; Bava, I.; Gliozzi, M.; Musolino, V.; Nucera, S.; Carresi, C.; Scicchitano, M.; Bosco, F.; Scarano, F.; et al. Myelin Disturbances Produced by Sub-Toxic Concentration of Heavy Metals: The Role of Oligodendrocyte Dysfunction. Int. J. Mol. Sci. 2019, 20, 4554, . [CrossRef]
- Belov Kirdajova, D.; Kriska, J.; Tureckova, J.; Anderova, M. Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells. Front. Cell. Neurosci. 2020, 14, 51, . [CrossRef]
- Hill, R.A.; Patel, K.D.; Goncalves, C.M.; Grutzendler, J.; Nishiyama, A. Modulation of Oligodendrocyte Generation during a Critical Temporal Window after NG2 Cell Division. Nat. Neurosci. 2014, 17, 1518–1527, . [CrossRef]
- Dimou, L.; Gallo, V. NG 2-glia and Their Functions in the Central Nervous System. Glia 2015, 63, 1429–1451, . [CrossRef]
- Xu, G.; Wang, W.; Zhou, M. Spatial Organization of NG2 Glial Cells and Astrocytes in Rat Hippocampal CA1 Region. Hippocampus 2014, 24, 383–395, . [CrossRef]
- Ferrara, G.; Errede, M.; Girolamo, F.; Morando, S.; Ivaldi, F.; Panini, N.; Bendotti, C.; Perris, R.; Furlan, R.; Virgintino, D.; et al. NG2, a Common Denominator for Neuroinflammation, Blood–Brain Barrier Alteration, and Oligodendrocyte Precursor Response in EAE, Plays a Role in Dendritic Cell Activation. Acta Neuropathol. (Berl.) 2016, 132, 23–42, . [CrossRef]
- Zhang, S.; Wang, Q.; Yang, Q.; Gu, H.; Yin, Y.; Li, Y.; Hou, J.; Chen, R.; Sun, Q.; Sun, Y.; et al. NG2 Glia Regulate Brain Innate Immunity via TGF-Β2/TGFBR2 Axis. BMC Med. 2019, 17, 204, . [CrossRef]
- Hu, X.; Geng, P.; Zhao, X.; Wang, Q.; Liu, C.; Guo, C.; Dong, W.; Jin, X. The NG2-Glia Is a Potential Target to Maintain the Integrity of Neurovascular Unit after Acute Ischemic Stroke. Neurobiol. Dis. 2023, 180, 106076, . [CrossRef]
- Timmermann, A.; Tascio, D.; Jabs, R.; Boehlen, A.; Domingos, C.; Skubal, M.; Huang, W.; Kirchhoff, F.; Henneberger, C.; Bilkei-Gorzo, A.; et al. Dysfunction of NG2 Glial Cells Affects Neuronal Plasticity and Behavior. Glia 2023, 71, 1481–1501, . [CrossRef]
- Vélez-Fort, M.; Maldonado, P.P.; Butt, A.M.; Audinat, E.; Angulo, M.C. Postnatal Switch from Synaptic to Extrasynaptic Transmission between Interneurons and NG2 Cells. J. Neurosci. 2010, 30, 6921–6929, . [CrossRef]
- Shoemaker, W.R.; Chen, D.; Garud, N.R. Comparative Population Genetics in the Human Gut Microbiome. Genome Biol. Evol. 2022, 14, evab116, . [CrossRef]
- Chatterjee, G.; Negi, S.; Basu, S.; Faintuch, J.; O’Donovan, A.; Shukla, P. Microbiome Systems Biology Advancements for Natural Well-Being. Sci. Total Environ. 2022, 838, 155915, . [CrossRef]
- VanEvery, H.; Franzosa, E.A.; Nguyen, L.H.; Huttenhower, C. Microbiome Epidemiology and Association Studies in Human Health. Nat. Rev. Genet. 2023, 24, 109–124, . [CrossRef]
- Hou, K.; Wu, Z.-X.; Chen, X.-Y.; Wang, J.-Q.; Zhang, D.; Xiao, C.; Zhu, D.; Koya, J.B.; Wei, L.; Li, J.; et al. Microbiota in Health and Diseases. Signal Transduct. Target. Ther. 2022, 7, 135, . [CrossRef]
- Logsdon, A.F.; Erickson, M.A.; Rhea, E.M.; Salameh, T.S.; Banks, W.A. Gut Reactions: How the Blood–Brain Barrier Connects the Microbiome and the Brain. Exp. Biol. Med. 2018, 243, 159–165, . [CrossRef]
- Hrncir, T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms 2022, 10, 578, . [CrossRef]
- Sharma, G.; Biswas, S.S.; Mishra, J.; Navik, U.; Kandimalla, R.; Reddy, P.H.; Bhatti, G.K.; Bhatti, J.S. Gut Microbiota Dysbiosis and Huntington’s Disease: Exploring the Gut-Brain Axis and Novel Microbiota-Based Interventions. Life Sci. 2023, 328, 121882, . [CrossRef]
- Badal, V.D.; Vaccariello, E.D.; Murray, E.R.; Yu, K.E.; Knight, R.; Jeste, D.V.; Nguyen, T.T. The Gut Microbiome, Aging, and Longevity: A Systematic Review. Nutrients 2020, 12, 3759, . [CrossRef]
- Tong, H.; Yang, T.; Xu, S.; Li, X.; Liu, L.; Zhou, G.; Yang, S.; Yin, S.; Li, X.-J.; Li, S. Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies. Int. J. Mol. Sci. 2024, 25, 3845, . [CrossRef]
- Strandwitz, P. Neurotransmitter Modulation by the Gut Microbiota. Brain Res. 2018, 1693, 128–133, . [CrossRef]
- Li, Y.; Li, Y.-J.; Zhu, Z.-Q. To Re-Examine the Intersection of Microglial Activation and Neuroinflammation in Neurodegenerative Diseases from the Perspective of Pyroptosis. Front. Aging Neurosci. 2023, 15, 1284214, . [CrossRef]
- Buret, A.G.; Motta, J.-P.; Allain, T.; Ferraz, J.; Wallace, J.L. Pathobiont Release from Dysbiotic Gut Microbiota Biofilms in Intestinal Inflammatory Diseases: A Role for Iron? J. Biomed. Sci. 2019, 26, 1, . [CrossRef]
- Follmer, C. Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID -19 on Parkinson’s Disease. Mov. Disord. 2020, 35, 1495–1496, . [CrossRef]
- Silva, Y.P.; Bernardi, A.; Frozza, R.L. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front. Endocrinol. 2020, 11, 25, . [CrossRef]
- Canani, R.B. Potential Beneficial Effects of Butyrate in Intestinal and Extraintestinal Diseases. World J. Gastroenterol. 2011, 17, 1519, . [CrossRef]
- Skrzypczak-Wiercioch, A.; Sałat, K. Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use. Molecules 2022, 27, 5481, . [CrossRef]
- Mitrea, L.; Nemeş, S.-A.; Szabo, K.; Teleky, B.-E.; Vodnar, D.-C. Guts Imbalance Imbalances the Brain: A Review of Gut Microbiota Association With Neurological and Psychiatric Disorders. Front. Med. 2022, 9, 813204, . [CrossRef]
- Christovich, A.; Luo, X.M. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Front. Immunol. 2022, 13, 946248, . [CrossRef]
- Camilleri, M. Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans. Gut 2019, 68, 1516–1526, . [CrossRef]
- Wasser, C.I.; Mercieca, E.-C.; Kong, G.; Hannan, A.J.; McKeown, S.J.; Glikmann-Johnston, Y.; Stout, J.C. Gut Dysbiosis in Huntington’s Disease: Associations among Gut Microbiota, Cognitive Performance and Clinical Outcomes. Brain Commun. 2020, 2, fcaa110, . [CrossRef]
- Witkowska, D.; Słowik, J.; Chilicka, K. Heavy Metals and Human Health: Possible Exposure Pathways and the Competition for Protein Binding Sites. Molecules 2021, 26, 6060, . [CrossRef]
- Koch, W.; Czop, M.; Iłowiecka, K.; Nawrocka, A.; Wiącek, D. Dietary Intake of Toxic Heavy Metals with Major Groups of Food Products—Results of Analytical Determinations. Nutrients 2022, 14, 1626, . [CrossRef]
- Rieder, G.S.; Duarte, T.; Delgado, C.P.; Rodighiero, A.; Nogara, P.A.; Orian, L.; Aschner, M.; Dalla Corte, C.L.; Da Rocha, J.B.T. Interplay between Diphenyl Diselenide and Copper: Impact on D. Melanogaster Survival, Behavior, and Biochemical Parameters. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2024, 281, 109899, . [CrossRef]
- Anand, I.S.; Gupta, P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation 2018, 138, 80–98, . [CrossRef]
- Yousefi Babadi, V.; Sadeghi, L.; Shirani, K.; Malekirad, A.A.; Rezaei, M. The Toxic Effect of Manganese on the Acetylcholinesterase Activity in Rat Brains. J. Toxicol. 2014, 2014, 1–4, . [CrossRef]
- Horning, K.J.; Caito, S.W.; Tipps, K.G.; Bowman, A.B.; Aschner, M. Manganese Is Essential for Neuronal Health. Annu. Rev. Nutr. 2015, 35, 71–108, . [CrossRef]
- Andrade, V.; Mateus, M.L.; Batoréu, M.C.; Aschner, M.; Dos Santos, A.M. Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese. EC Pharmacol. Toxicol. 2017, 3, 31–42.
- Peres, T.V.; Schettinger, M.R.C.; Chen, P.; Carvalho, F.; Avila, D.S.; Bowman, A.B.; Aschner, M. Manganese-Induced Neurotoxicity: A Review of Its Behavioral Consequences and Neuroprotective Strategies. BMC Pharmacol. Toxicol. 2016, 17, 57, . [CrossRef]
- O’Neal, S.L.; Zheng, W. Manganese Toxicity Upon Overexposure: A Decade in Review. Curr. Environ. Health Rep. 2015, 2, 315–328, . [CrossRef]
- Burton, N.C.; Schneider, J.S.; Syversen, T.; Guilarte, T.R. Effects of Chronic Manganese Exposure on Glutamatergic and GABAergic Neurotransmitter Markers in the Nonhuman Primate Brain. Toxicol. Sci. Off. J. Soc. Toxicol. 2009, 111, 131–139, . [CrossRef]
- Aschner, M.; Gannon, M. Manganese (Mn) Transport across the Rat Blood-Brain Barrier: Saturable and Transferrin-Dependent Transport Mechanisms. Brain Res. Bull. 1994, 33, 345–349, . [CrossRef]
- Aschner, M.; Skalny, A.V.; Martins, A.C.; Sinitskii, A.I.; Farina, M.; Lu, R.; Barbosa, F.; Gluhcheva, Y.G.; Santamaria, A.; Tinkov, A.A. Ferroptosis as a Mechanism of Non-Ferrous Metal Toxicity. Arch. Toxicol. 2022, 96, 2391–2417, . [CrossRef]
- Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascón, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017, 171, 273–285, . [CrossRef]
- Tang, D.; Chen, X.; Kang, R.; Kroemer, G. Ferroptosis: Molecular Mechanisms and Health Implications. Cell Res. 2021, 31, 107–125, . [CrossRef]
- Ji, Y.; Zheng, K.; Li, S.; Ren, C.; Shen, Y.; Tian, L.; Zhu, H.; Zhou, Z.; Jiang, Y. Insight into the Potential Role of Ferroptosis in Neurodegenerative Diseases. Front. Cell. Neurosci. 2022, 16, 1005182, . [CrossRef]
- Lee, J.-Y.; Kim, W.K.; Bae, K.-H.; Lee, S.C.; Lee, E.-W. Lipid Metabolism and Ferroptosis. Biology 2021, 10, 184, . [CrossRef]
- Tian, H.-Y.; Huang, B.-Y.; Nie, H.-F.; Chen, X.-Y.; Zhou, Y.; Yang, T.; Cheng, S.-W.; Mei, Z.-G.; Ge, J.-W. The Interplay between Mitochondrial Dysfunction and Ferroptosis during Ischemia-Associated Central Nervous System Diseases. Brain Sci. 2023, 13, 1367, . [CrossRef]
- Feng, S.; Tang, D.; Wang, Y.; Li, X.; Bao, H.; Tang, C.; Dong, X.; Li, X.; Yang, Q.; Yan, Y.; et al. The Mechanism of Ferroptosis and Its Related Diseases. Mol. Biomed. 2023, 4, 33, . [CrossRef]
- Li, J.; Cao, F.; Yin, H.; Huang, Z.; Lin, Z.; Mao, N.; Sun, B.; Wang, G. Ferroptosis: Past, Present and Future. Cell Death Dis. 2020, 11, 88, . [CrossRef]
- Jiang, X.; Stockwell, B.R.; Conrad, M. Ferroptosis: Mechanisms, Biology and Role in Disease. Nat. Rev. Mol. Cell Biol. 2021, 22, 266–282, . [CrossRef]
- Reichert, C.O.; de Freitas, F.A.; Sampaio-Silva, J.; Rokita-Rosa, L.; Barros, P. de L.; Levy, D.; Bydlowski, S.P. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases. Int. J. Mol. Sci. 2020, 21, 8765, . [CrossRef]
- Johnson, E.B.; Parker, C.S.; Scahill, R.I.; Gregory, S.; Papoutsi, M.; Zeun, P.; Osborne-Crowley, K.; Lowe, J.; Nair, A.; Estevez-Fraga, C.; et al. Altered Iron and Myelin in Premanifest Huntington’s Disease More than 20 Years before Clinical Onset: Evidence from the Cross-Sectional HD Young Adult Study. EBioMedicine 2021, 65, 103266, . [CrossRef]
- Levi, S.; Ripamonti, M.; Moro, A.S.; Cozzi, A. Iron Imbalance in Neurodegeneration. Mol. Psychiatry 2024, . [CrossRef]
- Mancardi, D.; Mezzanotte, M.; Arrigo, E.; Barinotti, A.; Roetto, A. Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver. Antioxid. Basel Switz. 2021, 10, 1864, . [CrossRef]
- Tang, Q.; Liu, H.; Shi, X.-J.; Cheng, Y. Blood Oxidative Stress Marker Aberrations in Patients with Huntington’s Disease: A Meta-Analysis Study. Oxid. Med. Cell. Longev. 2020, 2020, 9187195, . [CrossRef]
- Paul, B.D.; Snyder, S.H. Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications. Front. Mol. Neurosci. 2019, 12, 68, . [CrossRef]
- Jarosińska, O.D.; Rüdiger, S.G.D. Molecular Strategies to Target Protein Aggregation in Huntington’s Disease. Front. Mol. Biosci. 2021, 8, 769184, . [CrossRef]
- Chen, J.; Marks, E.; Lai, B.; Zhang, Z.; Duce, J.A.; Lam, L.Q.; Volitakis, I.; Bush, A.I.; Hersch, S.; Fox, J.H. Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine. PLoS ONE 2013, 8, e77023, . [CrossRef]
- Zhu, L.; Li, G.; Liang, Z.; Qi, T.; Deng, K.; Yu, J.; Peng, Y.; Zheng, J.; Song, Y.; Chang, X. Microbiota-Assisted Iron Uptake Promotes Immune Tolerance in the Intestine. Nat. Commun. 2023, 14, 2790, . [CrossRef]
- Correnti, M.; Gammella, E.; Cairo, G.; Recalcati, S. Iron Absorption: Molecular and Pathophysiological Aspects. Metabolites 2024, 14, 228, . [CrossRef]
- Patanè, G.T.; Putaggio, S.; Tellone, E.; Barreca, D.; Ficarra, S.; Maffei, C.; Calderaro, A.; Laganà, G. Ferroptosis: Emerging Role in Diseases and Potential Implication of Bioactive Compounds. Int. J. Mol. Sci. 2023, 24, 17279, . [CrossRef]
- Sun, S.; Shen, J.; Jiang, J.; Wang, F.; Min, J. Targeting Ferroptosis Opens New Avenues for the Development of Novel Therapeutics. Signal Transduct. Target. Ther. 2023, 8, 372, . [CrossRef]
- Li, Z.; Zhang, Y.; Ji, M.; Wu, C.; Zhang, Y.; Ji, S. Targeting Ferroptosis in Neuroimmune and Neurodegenerative Disorders for the Development of Novel Therapeutics. Biomed. Pharmacother. 2024, 176, 116777, . [CrossRef]
- Aschner, J.L.; Aschner, M. Nutritional Aspects of Manganese Homeostasis. Mol. Aspects Med. 2005, 26, 353–362, . [CrossRef]
- Li, L.; Yang, X. The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions. Oxid. Med. Cell. Longev. 2018, 2018, 1–11, . [CrossRef]
- Tizabi, Y.; Getachew, B.; Aschner, M. Butyrate Protects and Synergizes with Nicotine against Iron- and Manganese-Induced Toxicities in Cell Culture. Neurotox. Res. 2024, 42, 3, . [CrossRef]
- Evans, G.R.; Masullo, L.N. Manganese Toxicity. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2024.
- Porru, S.; Esplugues, A.; Llop, S.; Delgado-Saborit, J.M. The Effects of Heavy Metal Exposure on Brain and Gut Microbiota: A Systematic Review of Animal Studies. Environ. Pollut. 2024, 348, 123732, . [CrossRef]
- Aschner, M.; Martins, A.C.; Oliveira-Paula, G.H.; Skalny, A.V.; Zaitseva, I.P.; Bowman, A.B.; Kirichuk, A.A.; Santamaria, A.; Tizabi, Y.; Tinkov, A.A. Manganese in Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: The State of the Art. Curr. Res. Toxicol. 2024, 6, 100170, . [CrossRef]
- Bryan, M.R.; Bowman, A.B. Manganese and the Insulin-IGF Signaling Network in Huntington’s Disease and Other Neurodegenerative Disorders. In Neurotoxicity of Metals; Aschner, M., Costa, L.G., Eds.; Advances in Neurobiology; Springer International Publishing: Cham, 2017; Vol. 18, pp. 113–142 ISBN 978-3-319-60188-5.
- Cordeiro, L.M.; Soares, M.V.; Da Silva, A.F.; Dos Santos, L.V.; De Souza, L.I.; Da Silveira, T.L.; Baptista, F.B.O.; De Oliveira, G.V.; Pappis, C.; Dressler, V.L.; et al. Toxicity of Copper and Zinc Alone and in Combination in Caenorhabditis Elegans Model of Huntington’s Disease and Protective Effects of Rutin. NeuroToxicology 2023, 97, 120–132, . [CrossRef]
- Royer, A.; Sharman, T. Copper Toxicity. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2024.
- Opazo, C.M.; Lotan, A.; Xiao, Z.; Zhang, B.; Greenough, M.A.; Lim, C.M.; Trytell, H.; Ramírez, A.; Ukuwela, A.A.; Mawal, C.H.; et al. Nutrient Copper Signaling Promotes Protein Turnover by Allosteric Activation of Ubiquitin E2D Conjugases 2021.
- Immergluck, J.; Anilkumar, A.C. Wilson Disease. In StatPearls; StatPearls Publishing: Treasure Island (FL), 2024.
- Xiao, G.; Fan, Q.; Wang, X.; Zhou, B. Huntington Disease Arises from a Combinatory Toxicity of Polyglutamine and Copper Binding. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 14995–15000, . [CrossRef]
- Pfalzer, A.C.; Yan, Y.; Kang, H.; Totten, M.; Silverman, J.; Bowman, A.B.; Erikson, K.; Claassen, D.O. Alterations in Metal Homeostasis Occur Prior to Canonical Markers in Huntington Disease. Sci. Rep. 2022, 12, 10373, . [CrossRef]
- Rosas, H.D.; Chen, Y.I.; Doros, G.; Salat, D.H.; Chen, N.; Kwong, K.K.; Bush, A.; Fox, J.; Hersch, S.M. Alterations in Brain Transition Metals in Huntington Disease: An Evolving and Intricate Story. Arch. Neurol. 2012, 69, 887–893, . [CrossRef]
- Suganya, K.; Koo, B.-S. Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. Int. J. Mol. Sci. 2020, 21, 7551, . [CrossRef]
- Love, C.J.; Masson, B.A.; Gubert, C.; Hannan, A.J. The Microbiota-Gut-Brain Axis in Huntington’s Disease. In International Review of Neurobiology; Elsevier, 2022; Vol. 167, pp. 141–184 ISBN 978-0-323-99176-6.
- Wronka, D.; Karlik, A.; Misiorek, J.O.; Przybyl, L. What the Gut Tells the Brain—Is There a Link between Microbiota and Huntington’s Disease? Int. J. Mol. Sci. 2023, 24, 4477, . [CrossRef]
- Ekwudo, M.N.; Gubert, C.; Hannan, A.J. The Microbiota–Gut–Brain Axis in Huntington’s Disease: Pathogenic Mechanisms and Therapeutic Targets. FEBS J. 2024, febs.17102, . [CrossRef]
- Getachew, B.; Csoka, A.B.; Bhatti, A.; Copeland, R.L.; Tizabi, Y. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson’s Disease. Neurotox. Res. 2020, 38, 596–602, . [CrossRef]
- Getachew, B.; Csoka, A.B.; Garden, A.R.; Copeland, R.L.; Tizabi, Y. Sodium Butyrate Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line. Neurotox. Res. 2021, 39, 2186–2193, . [CrossRef]
- Batista, C.R.A.; Gomes, G.F.; Candelario-Jalil, E.; Fiebich, B.L.; de Oliveira, A.C.P. Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. Int. J. Mol. Sci. 2019, 20, 2293, . [CrossRef]
- Breit, S.; Kupferberg, A.; Rogler, G.; Hasler, G. Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. Front. Psychiatry 2018, 9, 44, . [CrossRef]
- Gubert, C.; Love, C.J.; Kodikara, S.; Mei Liew, J.J.; Renoir, T.; Lê Cao, K.-A.; Hannan, A.J. Gene-Environment-Gut Interactions in Huntington’s Disease Mice Are Associated with Environmental Modulation of the Gut Microbiome. iScience 2022, 25, 103687, . [CrossRef]
- Tang, W.; Zhu, H.; Feng, Y.; Guo, R.; Wan, D. The Impact of Gut Microbiota Disorders on the Blood–Brain Barrier. Infect. Drug Resist. 2020, Volume 13, 3351–3363, . [CrossRef]
- Vauleon, S.; Schutz, K.; Massonnet, B.; Gruben, N.; Manchester, M.; Buehler, A.; Schick, E.; Boak, L.; Hawellek, D.J. Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies. Sci Rep. 2023, 13, 5332, . [CrossRef]
- Juarez, D.; Handal-Silva, A.; Morán-Perales, J.L.; Torres-Cifuentes, D.M.; Flores, G.; Treviño, S.; Moreno-Rodriguez, A.; Guevara, J.; Diaz, A. New insights into sodium phenylbutyrate as a pharmacotherapeutic option for neurological disorders. Synapse. 2024, Jul;78(4):e22301. PMID: 38819491. [CrossRef]
- Khoshnan, A. Gut Microbiota as a Modifier of Huntington's Disease Pathogenesis. J Huntingtons Dis. 2024, E-Pub ahead of print, doi: 10.3233/JHD-240012.
- Ma, Y.Y.; Li, X.; Yu, J.T.; Wang, Y.J. Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside. Transl Neurodegener. 2024, 13(1):12. [CrossRef]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).